HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Dr. Reddy’s Laboratories launches novel molecule ‘Tegoprazan’ in India
Sep-16-2025

Dr. Reddy’s Laboratories has launched the novel molecule ‘Tegoprazan’, for acid-related gastrointestinal diseases in India. The company launches Tegoprazan (50 mg) under the brand name PCAB. Tegoprazan is a next-generation potassium-competitive acid blocker. It is indicated for the treatment of acid peptic diseases (APD) such as Erosive Gastroesophageal Reflux Disease (GERD), Non-Erosive Gastroesophageal Reflux Disease (NERD) and Gastric Ulcer. Tegoprazan induces fast onset of action and can control gastric pH for a prolonged period, potentially offering significant clinical benefit in APD management.

Recent data indicates that APD affects around 38% of the Indian population, highlighting its widespread prevalence and the growing need for effective management strategies. The launch of Tegoprazan by the company aims to bridge the gap in the treatment option for acid peptic diseases. In a multinational clinical trial conducted by the company across India, South Africa and Russia, 99% of GERD patients in the Tegoprazan treatment arm achieved endoscopic healing by Week 8. Tegoprazan is already approved in 21 countries, including South Korea and China. It is currently under registration in several countries and has successfully completed Phase-III trial in the United States.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

  RELATED NEWS >>